4DMedical Limited (4DX.XA)
Cboe AU · AUD
A$3.62 (-1.55%) as of
Key statistics
- EPS (TTM)
- -0.0770
- 52-week range
- 1.4050 – 7.5500
- Beta
- 1.84
- Revenue (TTM)
- 7.06M
- Profit margin
- 0.00%
- Volume
- 460.36k
About 4DMedical Limited
4DMedical Limited operates as a medical technology company in the United States and Australia. The company engages in medical research technology and development of a non invasive respiratory imaging solution. It offers CT:VQ, non-contrast post processing technology; CAC, a non-contrast cardiothoracic risk assessment sotware; CT LVAS, a regional lung function imaging software; IQ-UIP, a state-of-the-art software; LDAf, Patented Parametric Response Mapping (PRM) technology; LDAi, an automated detection of potential emphysema software; LTA provides visualization and quantification of the lung textures; PHA Analysis, a cutting-edge, fully-automated imaging solution; XV LVAS, a lung airflow imaging software; and XV Scanner, a lung function scanner. The company has partnership with AstraZeneca to launch and expand a lung health screening program; and a contractual engagement with GlaxoSmithKline to provide its proprietary quantitative lung imaging analytics in support of pulmonary drug development and clinical research. 4DMedical Limited was incorporated in 2012 and is based in Carlton, Australia.
- Headquarters
- Carlton, VIC, Australia
- Employees
- 181
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.